- Trials with a EudraCT protocol (38)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
38 result(s) found for: Bladder Neck.
Displaying page 1 of 2.
| EudraCT Number: 2007-001268-57 | Sponsor Protocol Number: 905-CL-058 | Start Date*: 2007-09-12 | ||||||||||||||||
| Sponsor Name:Astellas Pharma US, Inc. | ||||||||||||||||||
| Full Title: A Phase 2, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multi-Center Study to Evaluate the Safety of the Co-administration of Solifenacin Succinate with 0.4 mg Tamsulosin Hydrochlo... | ||||||||||||||||||
| Medical condition: Storage and Voiding Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO) | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male | |||||||||||||||||
| Trial protocol: CZ (Completed) BE (Completed) HU (Completed) DE (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2008-007053-13 | Sponsor Protocol Number: STEG-CORP_111802 | Start Date*: 2009-07-31 | |||||||||||
| Sponsor Name:Grachtenhaus-Apotheke, Inh. Klaus Stegemann e. K. | |||||||||||||
| Full Title: Doppelblinde, randomisierte, Placebo-kontrollierte Studie der Phase III zur Bestimmung der Wirksamkeit, Verträglichkeit und Sicherheit von intravesikal verabreichter Oxybutynin-Lösung bei Kindern/J... | |||||||||||||
| Medical condition: bladder disorder (detrusor hyperactivity caused by neurogenic disorder) | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2016-004743-37 | Sponsor Protocol Number: GCT1015-03 | Start Date*: 2017-03-28 | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Genmab A/S | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: A multi-center, open-label trial investigating the efficacy and safety of continued treatment with tisotumab vedotin in patients with solid tumors known to express tissue factor | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Cancer of the ovary, cervix, endometrium, bladder, prostate (castrationresistant prostate cancer [CRPC]), esophagus, lung (non-small cell lung cancer [NSCLC]), and Squamous cell carcinoma of the he... | |||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: BE (Completed) GB (Completed) SE (Completed) HU (Completed) DK (Prematurely Ended) | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2009-011843-38 | Sponsor Protocol Number: STEG-CORP_111804 | Start Date*: 2009-12-07 | |||||||||||
| Sponsor Name:Grachtenhaus-Apotheke, Inh. Klaus Stegemann e.K. | |||||||||||||
| Full Title: Documentation of the efficacy and tolerability of intravesically applied oxybutynin solution in adult patients with detrusor hyperactivity caused by neurological disorder | |||||||||||||
| Medical condition: Detrusor hyperactivity caused by neurological dysfunction | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2006-006935-38 | Sponsor Protocol Number: A0221008 | Start Date*: 2007-04-16 | |||||||||||
| Sponsor Name:Pfizer Inc. NYO-685-21-14,685 3rd Avenue, NEW YORK, NY 10017. US | |||||||||||||
| Full Title: 12-WEEK, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF FESOTERODINE IN COMPARISON TO TOLTERODINE ER IN PATIENT... | |||||||||||||
| Medical condition: Treatment of overactive bladder with symptoms of frequency, urgency, and urgency incontinence. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: SE (Completed) DE (Completed) ES (Completed) BE (Completed) HU (Completed) DK (Completed) CZ (Completed) GR (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2007-001451-19 | Sponsor Protocol Number: 178-CL-046 | Start Date*: 2008-06-05 | |||||||||||
| Sponsor Name:Astellas Pharma Europe B.V. | |||||||||||||
| Full Title: A Randomized, Double-blind, Parallel Group, Placebo and Active Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist YM178 (50 mg qd and 100 mg qd) in Subjects with ... | |||||||||||||
| Medical condition: Symptoms of Overactive Bladder | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) FI (Completed) SE (Completed) IS (Completed) CZ (Completed) LV (Completed) IE (Completed) GB (Completed) BE (Completed) FR (Completed) ES (Completed) HU (Completed) DK (Completed) LT (Completed) PT (Completed) IT (Completed) NL (Completed) AT (Completed) GR (Completed) SK (Completed) BG (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2016-001359-36 | Sponsor Protocol Number: CA223-001 | Start Date*: 2016-07-26 | |||||||||||
| Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
| Full Title: A Phase I /II Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-KIR (Lirilumab) Administered in Combination with Anti-PD-1 (Nivolumab) in Advanced Refracto... | |||||||||||||
| Medical condition: Solid tumors | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) FR (Ongoing) ES (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2006-000047-26 | Sponsor Protocol Number: AN05-7301 | Start Date*: 2006-03-10 |
| Sponsor Name:Leeds Teaching Hospitals NHS Trust | ||
| Full Title: A randomized controlled trial of caudal epidural or intravenous fentanyl on the post-operative analgesia requirements after transurethral endoscopic resection of prostate, bladder neck or bladder t... | ||
| Medical condition: Bladder spasm following endoscopic resection for: Bladder tumour Prostate hypertrophy Prostate cancer | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (GB - no longer in EU/EEA) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2021-000615-23 | Sponsor Protocol Number: UC-IMM-2101 | Start Date*: 2021-06-17 | ||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:UNICANCER | ||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: Randomized phase III trial of standard immunotherapy (IO) by checkpoint inhibitors, versus reduced dose intensity of IO in patients with metastatic cancer in response after 6 months of standard IO | ||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Oncologic metastatic tumour (lung cancer (K), renal cell K (except IMDC favorable-risk treated TKI / immunotherapy [IO] combination), head and neck K, bladder K, triple negative breast K, Merkel K ... | ||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: FR (Ongoing) | ||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2021-003026-69 | Sponsor Protocol Number: IO102-IO103-022 | Start Date*: 2022-05-09 | |||||||||||||||||||||
| Sponsor Name:IO Biotech ApS | |||||||||||||||||||||||
| Full Title: A Phase II Multi-Arm (basket) Trial Investigating the Safety and Efficacy of IO102-IO103 in Combination with Pembrolizumab, as First-line Treatment for Patients with Metastatic Non-Small Cell Lung ... | |||||||||||||||||||||||
| Medical condition: Metastatic Non-Small Cell Lung Cancer (NSCLC), Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN), Metastatic Urothelial Bladder Cancer (mUBC) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: ES (Ongoing) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2013-001699-39 | Sponsor Protocol Number: HER117158 | Start Date*: 2015-03-11 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:GlaxoSmithKline Research Development Ltd | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: A phase I, first time in human, open-label, dose escalation study to investigate the safety, pharmacokinetics, and pharmacodynamics of anti-HER3 monoclonal antibody GSK2849330 in subjects with adva... | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Subjects with advanced HER3-positive solid tumors | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: NL (Completed) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2016-000049-30 | Sponsor Protocol Number: RITE-2 | Start Date*: 2017-07-26 |
| Sponsor Name:Medical Enterprises Europe B.V | ||
| Full Title: A multicenter, single-arm study evaluating the efficacy of Synergo radiofrequency-induced thermochemotherapy effect (RITE) with Mitomycin C( Synergo + MMC) in non-muscle invasive bladder cancer (NM... | ||
| Medical condition: Non-Muscle-Invasive Bladder Cancer | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: AT (Prematurely Ended) ES (Prematurely Ended) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2010-020220-22 | Sponsor Protocol Number: H6D-MC-LVIR | Start Date*: 2010-12-21 | |||||||||||
| Sponsor Name:Eli Lilly and Company | |||||||||||||
| Full Title: A Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Effect of Tadalafil Once Daily for 8 Weeks on Prostatic Blood Flow and Perfusion Parameters in Men with Signs and Symptoms of Be... | |||||||||||||
| Medical condition: Benign Prostatic Hyperplasia (BPH) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male | ||||||||||||
| Trial protocol: BE (Completed) AT (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2014-001225-33 | Sponsor Protocol Number: UC-0105/1401 | Start Date*: 2014-07-21 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:UNICANCER | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: Secured access to vemurafenib for patients with tumors harboring BRAF genomic alterations. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Patient with BRAF V600 mutation determined on the primary and/or metastatic lesion in the following pathologies: . NSCLC . Ovarian cancer . Cholangiocarcinoma . Thyroid cancer . Prostatic canc... | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: FR (Ongoing) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2013-001074-15 | Sponsor Protocol Number: GEN701 | Start Date*: 2013-10-08 | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Genmab A/S | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: First-in-human, dose-escalating safety study of tissue factor specific antibody drug conjugate tisotumab vedotin (HuMax®-TF-ADC) in patients with locally advanced and/or metastatic solid tumors kno... | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Cancer of the ovary, cervix, endometrium, bladder, prostate (castration-resistant prostate cancer [CRPC]), head and neck (squamous cell carcinoma of the head and neck [SCCHN]), esophagus or lung (n... | |||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2019-000572-41 | Sponsor Protocol Number: LUC19-002 | Start Date*: 2019-04-29 |
| Sponsor Name:Cliniques Universitaires Saint-Luc | ||
| Full Title: An open label phase II study combining anti-PD-1 or PD-L1 and Celecoxib in patients with advanced « cold » solid tumors | ||
| Medical condition: Indication of treatment with anti-PD1 antibodies such as • Melanoma non BRAF mutated in first line of treatment • Melanoma BRAF mutated in first or second line of treatment • Lung cancer (NSCLC) in... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: BE (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2017-005057-36 | Sponsor Protocol Number: GLG-801-07 | Start Date*: 2018-05-17 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:GLG Pharma S.A. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: A Phase I/II Open-Label Study to Evaluate the Safety, Tolerability and Recommended Phase II Dose (RP2D) of GLG-801 in patients with Advanced Solid Tumors (Phase I); and safety, tolerability and ant... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Metastatic triple-negative breast cancer Breast cancer, prostate cancer, ovarian cancer, head and neck cancer, NSCLC, colorectal cancer, gastric cancer, esophageal cancer, bladder cancer, renal ce... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: PL (Ongoing) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2019-004875-38 | Sponsor Protocol Number: PRIMEH&N | Start Date*: 2020-11-12 | |||||||||||||||||||||
| Sponsor Name:Fondazione GONO | |||||||||||||||||||||||
| Full Title: The induction and maintenance treatment with PARP inhibitor and immunotherapy in HPV-negative Head and Neck Squamous Cell Carcinoma (HNSCC) | |||||||||||||||||||||||
| Medical condition: HPV-negative Head and Neck Squamous Cell Carcinoma (HNSCC) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: IT (Ongoing) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2017-000300-26 | Sponsor Protocol Number: E7080-A001-111 | Start Date*: 2017-10-20 | ||||||||||||||||||||||||||||||||||||
| Sponsor Name:Eisai Ltd. | ||||||||||||||||||||||||||||||||||||||
| Full Title: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors | ||||||||||||||||||||||||||||||||||||||
| Medical condition: Non-small cell lung cancer, predominantly clear cell renal cell carcinoma, endometrial carcinoma, urothelial carcinoma, squamous cell carcinoma of the head and neck, or melanoma (excluding uveal me... | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
| Trial protocol: ES (Ongoing) NO (Completed) | ||||||||||||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2016-004524-38 | Sponsor Protocol Number: GECP16/04 | Start Date*: 2017-03-06 |
| Sponsor Name:Spanish Lung Cancer Group (Grupo Español de Cáncer de Pulmón) | ||
| Full Title: A phase II exploratory study of durvalumab (MEDI4736) in HIV-1 patients with advanced solid tumors | ||
| Medical condition: advanced solid tumors in HIV-1 infected patients | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: ES (Completed) | ||
| Trial results: View results | ||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
